Supply Chains and Global Health: An Imperative for Bringing Operations Management Scholarship into Action by Kraiselburd, Santiago & Yadav, Prashant
Supply Chains and Global Health: An Imperative for
Bringing Operations Management Scholarship into
Action
Santiago Kraiselburd
Escuela de Negocios, Universidad Torcuato Di Tella, 1010 Calle Sáenz Valiente, Buenos Aires, Argentina, and INCAE Business School,
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M any people in developing countries do not have access to effective vaccines, medicines, and other life-saving healthtechnologies. Shortage of health care workers, severe financial constraints, and lack of awareness are some of the
major obstacles that prevent higher access. However, ineffective and poorly designed supply chains for purchasing and
distributing the medicines, vaccines, and health technologies are one of the most important barriers to increasing access.
We argue that the ineffectiveness of the global health supply chain can be attributed largely to: coordination problems
across multiple stakeholders with widely divergent objectives, lack of careful supply chain design, and use of myopic
operational objectives and metrics. The operations management research community can contribute to improving this by
applying existing knowledge to the field of global health delivery and by researching new frameworks of analysis which
would then become the cornerstones for policy advice to those who design, operate, or finance these supply chains.
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1. Introduction
Today, our collective scientific knowledge, technolog-
ical expertise, and economic resources add up to an
impressive arsenal that could be used to reduce the
unnecessary human suffering resulting from disease
and ill-health. Yet, world-wide, millions of people do
not have access to these effective vaccines, medicines,
and other life-saving health technologies. It is a sad
fact that, every year, around 10 million children
under the age of 5 die due to lack of access to simple
and affordable interventions (WHO 2008). For exam-
ple, despite significant progress in the prevention and
treatment of HIV/AIDS, it still remains the leading
cause of adult death in Africa, reducing life expec-
tancy in highly affected countries. It is estimated (Fos-
ter et al. 2006) that almost one-third of the world’s
population does not have access to essential medi-
cines. In addition to this, each year, personal expendi-
tures on health push more than 100 million people
below the poverty line (Xu et al. 2007).
Clearly, a key barrier that prevents higher access to
life-saving medicines and health technologies is pov-
erty itself. As mentioned, people in low- and middle-
income countries (and their governments) often lack
the money to purchase vaccines and essential medi-
cines. However, empirical evidence from such varied
places as Costa Rica, Sri Lanka, Kerala State in India,
and Mongolia has shown that income improvement is
not a prerequisite for better health outcomes (Cald-
well 1986, 1990, Halstead et al. 1985, Kim and Moody
1992). In fact, health can be improved before income
increases, as improved health appears to contribute to
economic growth (implying a reverse sign of causality
is also in play). Driven by this argument, more than
$27 billion is spent annually on global health by
multi-country financing organizations such as the
Global Fund to fight AIDS, TB, and Malaria; the
World Bank, UNITAID, Global Alliance on Vaccines
and Immunization (GAVI); and bilateral donors such
as the US government, the British Government, the
Bill & Melinda Gates Foundation; and others (Ravi-
shankar et al. 2009, Yadav 2010).
Ensuring better global health is obviously a com-
plex challenge that involves disentangling many
inter-connected causes and effects. Despite the exis-
tence of products, technology, and funds dedicated to
certain diseases, medicines for these diseases are still
not getting to the target population in the right quanti-
ties, at the right prices, at the right time, and in the
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right places. Given this, it is clear that a key barrier to
improved global health is the limited capacity in
resource-poor countries to procure, manufacture, or
distribute medicines, vaccines, and others products
and technologies that can improve health outcomes.
The average performance of health care supply chains
is much poorer in low- and middle-income countries
than in OECD nations, and varies substantially
between countries, regions, programs, delivery chan-
nels, and sub-populations. Performance also may
vary considerably over time. For example, it is esti-
mated that the average service level of drugs at public
health facilities is less than 25%, and even at private
outlets, where products are often unaffordable to
most of the population, availability is under 65%
(Cameron et al. 2009). This compares to an average
service level of 92.5% at the point of access in the EU-
15 (Macarthur 2007). The above clearly demonstrates
that the supply chain for global health is extremely
sick and deserves careful analysis using existing or
newly developed break only as analytical tools. A
deeper and structured understanding of the supply
chain for medicines in low- and middle-income coun-
tries would be key to the development of remedial
policy interventions that can improve access to medi-
cines and, consequently, health. As researchers, the
supply chains for medicines in many low- and mid-
dle-income countries present us with a unique oppor-
tunity to chart a course that is based on past learning
from the design of health care and other supply
chains in OECD countries.
2. Deficiencies in Global Health
Supply Chains and Areas for
Research
To help describe the situation, raise debate, and
motivate research in this topic, we suggest three main
areas where we believe the contribution of research-
ers from the field of operations and supply chain
management can have the greatest impact. These sug-
gestions are based on (i) a few preliminary studies
that were carried out by a team involving the authors
in a heterogenous set of three to four low- and mid-
dle-income countries, (ii) interviews with multiple
stakeholders over the last 2 years, and (iii) extensive
review of existing published and practioner literature
in this field.
2.1. Inefficiencies in Global Health Supply Chains
Often Result from Coordination Problems across
Multiple Stakeholders with Widely Divergent
Objectives
There exists a wide array of structural (and institu-
tional) possibilities in how the supply and distribu-
tion chains for medicines are organized in low- and
middle-income countries (Attridge and Preker 2000,
Govindaraj et al. 2000). Additionally, the agencies
involved in financing, policy making, and quality reg-
ulation also play an important role in the provision of
drugs and medical supplies. Figure 1 illustrates the
range of actors involved in financing and physical dis-
tribution of drugs and health commodities in low-
and middle-income countries. The problem is com-
pounded by the multiplicity of agents at each level:
for example, the public sector supply chain of Zambia
(not a particularly complex case) shows that 12 main
categories of health products were procured using 19
different sources of funding, using 17 different
procurement organizations, and over six first-tier
warehousing providers (Fundafunda and Yadav
2008). Thus, there is often a complex combination of
institutions specializing in funding, manufacturing,
import, wholesaling, retailing, and various other aux-
iliary functions that have to join forces in making the
drug available to the end-patient (Attridge and Preker
2000).
Many of the problems observed in the global health
supply chains are due to the complex interactions
between these multiple stakeholders with often con-
flicting objectives and scope. Although conflicting
objectives are not unique to global health supply
chains alone, in this case they often involve inter-
twined and convoluted social, economic, and political
interests. While it can be argued that the main objec-
tive of most agents in private supply chains in other
industries is profit or utility maximization, the moti-
vation behind some key agents in global health sup-
ply chains can be very different. For example, what
most donors seek can be summarized as “maximize
traceable impact on health for each dollar spent,
while minimizing corruption, waste, and risks in
general that can lead to bad publicity.” Traceability is
important for two inter-related reasons: it enables the
learning process by facilitating the isolation of causal
relationships, and it allows the donors to claim suc-
cess (which allows the donors to raise more funds
and help more people). The problem is that, to keep
traceability and to maximize transparency, efficiency,
coordination, and economies of scale are usually sac-
rificed. For example, while pooling of donor funds,
pooled purchasing of medicines, pooled transporta-
tion services, and pooled inventories can potentially
achieve significant savings, it would also conflict with
the traceability objectives: once it is all pooled, it is
difficult to trace the impact of a particular donor’s
contribution or to allocate resources based on differ-
ing priorities. Similar tensions arise between transpar-
ency, equity of access, efficiency, and responsiveness,
etc. The role of a supply-chain integrator that coordi-
nates some core functions across firm boundaries
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within a supply chain (Parker and Anderson 2002) is
currently non-existent in global health supply chains.
We conjecture that the lack of a common framework
for understanding these supply chains at least in part
contributes to this lack of goal congruence and the
resulting system-wide inefficiencies. Lack of a com-
mon framework of understanding inhibits the devel-
opment of better incentive alignment mechanisms or
new roles in the supply chain. Such a framework
needs to be built around a set of hierarchical metrics
for all the actors involved. The development of such a
framework requires new research as conventional
frameworks involving profit maximization or even
social welfare maximization do not necessarily apply
in this case.
2.2. Supply Chain Design for Global Health
Requires Careful Context-Specific Analysis Which
Is Very Often Lacking
A system for supplying medicines and health
commodities can be built using anything from a fully
publicly owned to a fully private system. Most
OECD countries use a fully privatized system for
drug supplies with the government role being lim-
ited to quality regulation and contracting. However,
in most low- and middle-income countries publicly
owned (and operated) central medical stores and
autonomous supply agencies are the most commonly
used drug supply systems (Seiter 2010). Some coun-
tries, such as Tanzania, Uganda, and Zambia, have
built their drug supply networks using para-statal
entities, whereas others, such as Malawi, have con-
tracted out the procurement, storage, and distribu-
tion of essential drugs to international agencies.
A plethora of situations exist, and it is not clear what
institutional structure works best under what condi-
tions.
Another question that remains unanswered is
whether the functions of medicine procurement or
distribution should be centralized at the national level
or decentralized at the district or the province level.
To further compound the complexity of options,
public vs. private and centralized vs. decentralized
decisions can be combined in different ways. For
example, some countries, such as Ghana, have decen-
tralized medicine procurement and distribution and
are allowing districts to purchase drugs and supplies
from private sector suppliers. It can be argued that
allowing district purchases from the private sector
creates competition for the public sector supply sys-
tem and may lead to improving its efficiency. How-
ever, it is not clear if the positive impact of
competition offsets the loss of scale economies that
exist in the public sector supply system. In addition to
this, the conventional trade-off between bargaining
power efficiencies of centralization and agility and
responsiveness of decentralization poses a unique
nuance here due to possible differences in transpar-



























International Financing Organizations Prescribers &
Dispensers
Government Budgets
Figure 1 Physical and Financial Flows in the Supply Chain for Drugs and Health Commodities in Low- and Middle-Income Countries (Only broad
level financial flows are depicted. There are other financial flows such as those flowing upstream from the end-patient and social insur-
ance schemes to the manufacturer.)
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At a more tactical level, it is not clear what is the
“right” number of tiers to have in a country’s national
drug supply system, the “right” number of competi-
tors within each tier, and whether vertical integration
across tiers helps or hinders performance. Here,
tensions between economies of scale and monopoly
power are clearly part of the issue. Regardless of the
degree of vertical integration or number of players
within layers, in most countries, irrespective of the
geographical size, population density or other charac-
teristics of the country, a three-tier system is utilized,
with stocking points at the central warehouse, district
or regional warehouses and the primary clinic level
(Yadav et al. 2011). A recent quasi-randomized study
in Zambia found large improvements in product
availability by reducing the number of tiers in the
supply system (Vledder et al. 2011).
It is also not clear if a single system is best suited
for all essential drugs and medical supplies. It may
well be that different systems are suited for different
categories of drugs and a careful segmentation of the
product categories is required before carrying out
such analysis.
Although numerous pilot projects are underway to
empirically test some of these issues, the world would
certainly benefit from more operations and supply
chain management researchers joining this debate.
2.3. Design Decisions for Global Health Supply
Chains Are Often Based on Myopic Operational
Objectives and Metrics
Adequate supply chain design should analyze the
physical product flow, information flow, and financial
flow. However, in a lot of the recent global health
initiatives that originated with new (or recently
expanded) donors, financial flows play the critical
role in design decisions for global health supply
chains. Part of the problem is that, as mentioned
earlier, supply chains designed around multiple but
non-coordinated financing streams often compromise
efficiencies in physical or informational flows. In
particular, the role of information flows tends to be
especially underemphasized in global health supply
chains (Levine et al. 2008). Although this may be just
a consequence of the fact that less information gener-
ally is available from developing nations, more
research on the value of information in the context of
global health supply chains, and on the design of
healthy information-generating ecosystems would
certainly improve the situation. As of now, in the
poorest developing nations, very little information is
available on market shares, prices at different stages
of the supply chains, and even final, end-user
demand. However, before resources are spent correct-
ing this situation, we should have to be able to answer
some key questions such as: If we did have more
information, what would we do with it? Who should
gather what information in a consistent and unbiased
manner (Oliva and Watson 2009)? Who should have
access to what information? Is more information
always better, ceteris paribus? What models best cap-
ture the value of information in this context?
3. Conclusion
We hope we were able to clearly convey that more
work is required to fully understand the dynamics of
global health supply chains, and to identify and imple-
ment opportunities for improvement. We also wish
that some of the preliminary work done by the authors
can provide guideposts for future work in this area.
We are convinced that our urgent task is to build on
the recent progress that health programs world-wide
are showing. We are also convinced that operations
management reseachers can contribute by applying
existing knowledge to global health delivery and by
researching new frameworks of analysis that could
become the cornerstones for policy advice to those
who design, operate, or finance these supply chains. If
they could, the millions of people whose health could
potentially improve would forever thank this contri-
bution of operations management.
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